Core Viewpoint - Chengdu XianDao Pharmaceutical Development Co., Ltd. expects significant growth in net profit for the year 2025, projecting an increase of 102.50% to 147.29% compared to the previous year [1] Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company between 104 million yuan and 127 million yuan for 2025, representing an increase of 52.64 million yuan to 75.64 million yuan from the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 106 million yuan and 129 million yuan, an increase of 48.56 million yuan to 71.56 million yuan, which corresponds to a growth of 84.55% to 124.59% year-on-year [1] Previous Year Performance - In 2024, the company reported a total profit of 62.76 million yuan, with a net profit attributable to shareholders of the parent company at 51.36 million yuan, and a net profit after deducting non-recurring gains and losses of 57.44 million yuan [2][1] Reasons for Performance Change - The company has established long-term stable collaborations with global partners, leading to steady growth in core business segments, particularly in DEL (Design, Synthesis, and Screening of Drug Libraries), which has maintained a high gross margin [3] - The UK subsidiary has further solidified the development of the FBDD/SBDD platform, contributing to revenue growth from key business segments and milestone income from client projects [3] - The OBT segment has shown significant commercial transformation, with revenue growth driven by the integration of delivery molecule services and the efficient operation of an automated high-throughput chemical synthesis platform [3] - The decrease in fair value losses from financial liabilities has also positively impacted the overall profit [4]